65,437 trials
Urinary Stress Incontinence
Primary: Local Anesthesia Satisfaction — 43; 3 participants
Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Number of Flare Events Per Time of Exposure to Study Medication — 0.54; 0.93 flare events per month — p=<0.0001
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 — -0.66; -0.82; -1.13; -1.40 Percent
Major Depressive Disorder
Primary: Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS) — -10.12; -6.39 units on a scale — p=<0.001
Hepatitis B
Primary: Number of Participants With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Specific Cut-off Values — 72; 71; 64 participants
Myocardial Infarction
Primary: The Composite of All-Cause Mortality or Complications of MI at 90 Days. — 86; 86; 81 participants — p=0.551
Meningitis · Meningococcemia · Neisseria Meningitidis
Primary: Geometric Mean Titers (GMT) of Serum Bactericidal Activity for Each Vaccine Serogroups Before and Post-vaccination. — 316.1; 126.5; 11411.9; 6720.1 Titers
Metastatic Breast Cancer
Primary: Tumor Response — 0; 1; 0; 4 participants
Heart Failure
Primary: Percentage of Patients Worsened for Clinical Composite Response — 21.5; 16 Percentage of participants worsened — p=0.10
Asthma
Primary: Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population — 26.4; 3.6 L/min — p=<0.001
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
Herpes Zoster · Pneumococcal Infection
Primary: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination — 448.5; 371.6 gpELISA units*/mL — p=0.244
Breast Cancer · Breast Neoplasms
Primary: Overall Tumor Response — 2; 0; 8; 5 participants
Hypercholesterolemia · Hyperlipidemia
Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) After 12 Weeks — -10.3; 4.4 Percent Change — p=<0.001
Fibromyalgia
Primary: Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14) — -0.73; -1.06; -1.29; -0.96 Units on a scale — p=0.2361